Please assess the completion status of the following clinical trial:

Trial Title: Cabergoline for Lactation Inhibition After Second-Trimester Abortion or Loss

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Pregnant people, ages 18 years or older~* Intrauterine pregnancy between 18/0-28/0 weeks of gestation age (by ultrasound dating performed prior to or same day of enrollment visit)~* Consented for an induced, elective abortion or undergoing induction for demise~* English or Spanish speaking~* Able to consent for a research study, literate in English or Spanish~* Willing to comply with study procedures and follow-up~* Access to smart phone throughout study~Exclusion Criteria:~* Prior mastectomy (breast reduction or chest masculinization surgery acceptable)~* Currently breastfeeding~* Currently receiving dopamine agonist therapy for other indication (prolactinoma, Cushings syndrome, acromegaly, restless leg syndrome)~* Contraindication to cabergoline (as per package insert)~  * Uncontrolled hypertension - defined as baseline BP \> 150/100, or chronic hypertension requiring more than one baseline medication, or pregnancy-induced hypertension spectrum disorders (gestational hypertension, preeclampsia, eclampsia)~ * History of cardiac valvular disorders or valvular repair~ * History of pulmonary, pericardial, or retroperitoneal fibrotic disorders

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cabergoline (Type: EXPERIMENTAL): After the completion of the surgical procedure or medical induction for the second-trimester abortion or fetal loss, the participant will be administered cabergoline 1mg orally with juice or water by the clinician or study investigator.
- Placebo (Type: PLACEBO_COMPARATOR): After the completion of the surgical procedure or medical induction for the second-trimester abortion or fetal loss, the participant will be administered a placebo pill orally with juice or water by the clinician or study investigator.

Based on this trial design, predict the completion outcome and termination type (if applicable).